We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed at $140.37 in the latest trading session, marking a -2.91% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.37%. Meanwhile, the Dow experienced a drop of 0.74%, and the technology-dominated Nasdaq saw a decrease of 0.03%.
The stock of kidney dialysis provider has risen by 1.41% in the past month, leading the Medical sector's loss of 0.88% and undershooting the S&P 500's gain of 2.68%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is scheduled to release its earnings on August 5, 2025. On that day, DaVita HealthCare is projected to report earnings of $2.7 per share, which would represent year-over-year growth of 4.25%. At the same time, our most recent consensus estimate is projecting a revenue of $3.3 billion, reflecting a 3.5% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $10.76 per share and revenue of $13.48 billion. These totals would mark changes of +11.16% and +5.15%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 13.44. Its industry sports an average Forward P/E of 18.09, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
It is also worth noting that DVA currently has a PEG ratio of 1. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.8 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 53, positioning it in the top 22% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA - Free Report) closed at $140.37 in the latest trading session, marking a -2.91% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.37%. Meanwhile, the Dow experienced a drop of 0.74%, and the technology-dominated Nasdaq saw a decrease of 0.03%.
The stock of kidney dialysis provider has risen by 1.41% in the past month, leading the Medical sector's loss of 0.88% and undershooting the S&P 500's gain of 2.68%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is scheduled to release its earnings on August 5, 2025. On that day, DaVita HealthCare is projected to report earnings of $2.7 per share, which would represent year-over-year growth of 4.25%. At the same time, our most recent consensus estimate is projecting a revenue of $3.3 billion, reflecting a 3.5% rise from the equivalent quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $10.76 per share and revenue of $13.48 billion. These totals would mark changes of +11.16% and +5.15%, respectively, from last year.
Any recent changes to analyst estimates for DaVita HealthCare should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 13.44. Its industry sports an average Forward P/E of 18.09, so one might conclude that DaVita HealthCare is trading at a discount comparatively.
It is also worth noting that DVA currently has a PEG ratio of 1. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.8 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 53, positioning it in the top 22% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.